连发9道风险提示后仍涨停，12天11板大牛股回应

Core Viewpoint - 合富中国 has experienced significant stock price increases, with a rise of over 200% in the last 12 trading days, leading to widespread market attention [1][2] Group 1: Stock Performance - On November 12, 合富中国's stock reached a closing price of 20.09 yuan per share, with a total market capitalization of 79.97 billion yuan [1] - The company has achieved 11涨停板 (daily price limits) in the recent trading period, indicating strong market interest [1] - The stock is currently at a historical high, with warnings from the company about potential market overreaction and irrational speculation [2] Group 2: Business Operations - 合富中国's main business remains unchanged, but it is currently operating at a loss, with a reported net loss of 12.39 million yuan for the first three quarters of the year [3] - The decline in revenue is attributed to price reductions from centralized procurement and a decrease in order volumes compared to the previous year [3] - The company is collaborating with Zhejiang University to develop an AI-assisted diagnostic system, with a contract value of 6.204 million yuan [2] Group 3: Market Environment - The medical commercial sector, including 合富中国, has been leading the A-share market, influenced by recent announcements regarding respiratory disease prevention [1] - The Shanghai Stock Exchange has flagged 合富中国 for significant trading anomalies, indicating potential regulatory scrutiny [2]